This Edition of the Genetic Technology TOE Depicts Life Sciences Trends Across Plasmid DNA and DNA Vaccine Technologies
This edition of the Genetic Technology TOE depicts life sciences trends across plasmid DNA and DNA vaccine technologies. The role of plasmid DNA manufacturing in the pharmaceutical industry, especially in cancer immunotherapy, is illustrated across industry profiles and notable innovations in the field. The corresponding clinical trial scenario for DNA vaccines is depicted, along with the industry interactions.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
Advancing Plasmid DNA and DNA Vaccine Technologies
- DNA Adjuvant Technology Granted US Patent
- Plasmid DNA Bioproduction Creates New Horizons in Human Health
- Efficient and Scalable DNA Production for Critical Emerging Diseases
- Investigational Platform for Cancer Immunotherapy
Clinical Trials Perspective and Industry Interactions
- Clinical Trials Perspective
- Industry Interactions
